Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida. The company went IPO on 2021-04-23. The company is advancing the standard of care for the surgical management of bunion and related midfoot deformities. The company has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. The company has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. The company sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.
最新の財務諸表(Form-10K)によると、Treace Medical Concepts Incの総資産は$190で、純損失は$-59です。
TMCIの主要な財務比率は何ですか?
Treace Medical Concepts Incの流動比率は1.84、純利益率は-27.83、1株当たり売上高は$3.35です。
Treace Medical Concepts Incの収益はセグメントまたは地域別にどのように分けられていますか?
Treace Medical Concepts Inc の最大収益セグメントは Medical Devices で、最新の利益発表における収益は 209,357,000 です。地域別に見ると、United States が Treace Medical Concepts Inc の主要市場であり、収益は 209,357,000 です。
Treace Medical Concepts Incは収益を上げていますか?
いいえ、最新の財務諸表によると、Treace Medical Concepts Incの純損失は$-59です。